

20th May 2023, 5:30pm - 8:00pm



## Scan or click to register

There will be 2 CPD points awarded for this event pending for approval from MMA





5:30pm	Registration	
6:00pm	Opening Remarks	Richard Abela Vice President and General Manager Novo Nordisk Malaysia
6:05pm	Welcome and introduction (Chair)	Emeritus Prof Dr Chan Siew Pheng
6:10pm	Role of Oral Semaglutide across the spectrum of diabetes journey	Prof Dr Norlela Sukor Dr Siti Harnida Md Isa Dr Hew Fen Lee
	Panel case discussion:  Newly diagnosed T2D as first-line-monotherapy –  early control matters	
	T2D uncontrolled on oral antidiabetic drug Optimizing outcome for patients on insulin	
6:40pm	Efficacy and Safety in patients with T2D and renal impairment	Dr Yew Shiong Shiong Dr Tan Li Ping Dr Ng Eng Khim
	Panel case discussion:	
	Optimizing outcomes for DKD patients	
	Obese DKD patients Safety and Efficacy in relatively poor eGFR	
7:20pm	Effects on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes	Dr Ng Wai Kiat Dr Emily Tan Lay Koon
	Panel case discussion:	
	Patient with multiple risk factors	
	Optimizing outcomes in T2D patients post angioplasty Post myocardial infarction patient	
8.00pm	Closing Remarks	



Richard Abela VP & GM, NN Malaysia



**Dr Hew Fen Lee**Consultant Endocrinologist,
Subang Jaya Medical Centre



Emeritus Prof Dr Chan Siew Pheng

Consultant Endocrinologist,

Subang Jaya Medical Centre



**Dr Yew Shiong Shiong**Consultant Nephrologist,

Mahkota Medical Centre



**Dr Ng Wai Kiat**Consultant Cardiologist,
Pantai Hospital Kuala Lumpur

**Fax**: +603 2276 5161 www.novonordisk.com



Prof Dr Norlela Sukor

Consultant Endocrinologist,

UKM Specialist Centre



**Dr Tan Li Ping**Consultant Nephrologist,
Ara Damansara Medical
Centre



**Dr Emily Tan Lay Koon**Consultant Cardiologist,

National Heart Institute Malaysia (IJN)



Dr Siti Harnida Md Isa Consultant Endocrinologist, Sunway Medical Centre



**Dr Ng Eng Khim**Consultant Nephrologist,

Sunway Medical Centre Subang

